abstract: OBJECTIVE: Variants in @entity15675 are associated with Lewy Body (LB) pathology. We investigated whether variants in other @entity2315 ( @entity2315 ) genes also contribute to disease pathogenesis. METHODS: We performed a genetic analysis of four @entity2315 genes including @entity15675 , @entity12744 , @entity54356 , and @entity49630 in 231 brain autopsies. Brain autopsies included neuropathologically defined @entity21244 without @entity195 ( @entity195 ) changes (n = 59), @entity195 without significant LB pathology (n = 71), @entity195 and lewy body variant (ADLBV) (n = 68), and control brains without LB or @entity195 neuropathology (n = 33). Sequencing of @entity12744 , @entity54356 , @entity49630 and @entity15675 followed by 'gene wise' genetic association analysis was performed. To determine the functional effect, a biochemical analysis of @entity15675 in a subset of brains was also performed. GCase activity was measured in a subset of brain samples (n = 64) that included @entity21244 brains, with or without @entity15675 mutations, and control brains. A lipidomic analysis was also performed in brain autopsies (n = 67) which included @entity21244 (n = 34), ADLBV (n = 3), @entity195 (n = 4), @entity1726 (n = 9) and control brains (n = 17), comparing @entity15675 mutation carriers to non-carriers. RESULTS: In a 'gene-wise' analysis, variants in @entity15675 , @entity54356 and @entity49630 were significantly associated with LB pathology (p range: 0.03-4.14 x10-5). Overall, the mean levels of GCase activity were significantly lower in @entity15675 mutation carriers compared to non-carriers (p<0.001). A significant increase and accumulation of several species for the lipid classes, @entity9932 and @entity13740 , was observed in @entity21244 brains carrying @entity15675 mutations compared to controls (p range: p<0.05-p<0.01). INTERPRETATION: Our study indicates that variants in @entity15675 , @entity54356 and @entity49630 are associated with LB pathology. Biochemical data comparing @entity15675 mutation carrier to non-carriers support these findings, which have important implications for biomarker development and therapeutic strategies.

title: Gene-wise association of variants in four XXXX genes in neuropathologically confirmed lewy body disease.

entities_list: @entity2315 :: ('MESH:D016464', 'Disease') :: ['lysosomal storage disorder', 'LSD']

entities_list: @entity13740 :: ('MESH:D013107', 'Chemical') :: ['sphingolipids']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['Alzheimer Disease', 'AD', 'Alzheimer disease']

entities_list: @entity9932 :: ('MESH:D002518', 'Chemical') :: ['ceramides']

answer: @entity2315 :: (MESH:D016464,Disease) :: ['lysosomal storage disorder']


abstract: Plants have evolved with intricate mechanisms to cope with multiple environmental stresses. To adapt with biotic and abiotic stresses, plant responses involve changes at the cellular and molecular levels. The current study was designed to investigate the effects of combinations of different environmental stresses on the transcriptome level of @entity958 genome using public microarray databases. We investigated the role of cyclopentenones in mediating plant responses to environmental stress through TGA (TGACG motif-binding factor) transcription factor, independently from jasmonic acid. Candidate genes were identified by comparing plants inoculated with @entity14261 or treated with heat, salt or osmotic stress with non-inoculated or non-treated tissues. About 2.5% heat-, 19% salinity- and 41% osmotic stress-induced genes were commonly upregulated by @entity14261 -treatment; and 7.6%, 19% and 48% of genes were commonly downregulated by @entity14261 -treatment, respectively. Our results indicate that plant responses to biotic and abiotic stresses are mediated by several common regulatory genes. Comparisons between transcriptome data from @entity958 stressed-plants support our hypothesis that some molecular and biological processes involved in biotic and abiotic stress response are conserved. Thirteen of the common regulated genes to abiotic and biotic stresses were studied in detail to determine their role in plant resistance to @entity14261 . Moreover, a T-DNA insertion mutant of the Responsive to Dehydration gene (rd20), encoding for a member of the caleosin (lipid surface protein) family, showed an enhanced sensitivity to @entity14261 @entity281 and drought. Overall, the overlapping of plant responses to abiotic and biotic stresses, coupled with the sensitivity of the rd20 mutant, may provide new interesting programs for increased plant resistance to multiple environmental stresses, and ultimately increases its chances to survive. Future research directions towards a better dissection of the potential crosstalk between @entity14261 , abiotic stress, and oxylipin signaling are of our particular interest.

title: Identification of XXXX candidate genes in response to biotic and abiotic stresses using comparative microarrays.

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis']

entities_list: @entity14261 :: ('40559', 'Species') :: ['B. cinerea', 'Botrytis cinerea']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

answer: @entity958 :: (3702,Species) :: ['Arabidopsis']


abstract: OBJECTIVE: Evidence suggests that an acute systemic inflammatory response is invoked after consumption of a high-energy meal. Postprandial regulation of @entity1254 , an adipose tissue-derived, anti-inflammatory hormone, and the gelatinases, @entity1476 and @entity1495 , endopeptidases implicated in a diverse range of inflammatory processes, remain inconclusive. The aim of this study was to assess the postprandial effect of a high-energy (1212  kcal) meal on plasma @entity1254 , @entity1476 and @entity1495 activity, @entity413 , insulin, @entity1674 , total @entity165 , high-density lipoprotein @entity165 , and the differential effects on these parameters depending on whether the test meal was high fat (HF; 46  g fat, 1210  kcal) or isoenergetic and low fat (LF; 15  g fat, 1214  kcal energy). METHODS: Test meals were consumed by 17 lean, healthy @entity1 on two separate occasions with blood samples collected by venipuncture at baseline (0  h) and 1 and 3  h after consumption of each test meal. RESULTS: At baseline, no significant difference was seen in the parameters between the two groups, except for @entity1476 , @entity1495 , and total @entity165 . Over the 3-h postprandial period, no significant differential effect of the HF versus the LF test meal was observed on @entity1254 , @entity1476 , @entity1495 , or on metabolic markers other than @entity1674 , which increased significantly in response to the HF test meal (time  *  treatment, P  =  0.002). When analyzed independent of time, @entity1476 (treatment, P  =  0.006), @entity1495 (treatment, P  =  0.022), and @entity413 (treatment, P  =  0.026) were lower after consumption of the HF meal compared with the LF test meal. When analyzed independent of treatment, @entity1254 increased over the 3-h postprandial period (time, P  =  0.031), but there was no change in @entity1476 or @entity1495 (time, P  =  0.503 and P  =  0.525, respectively). Over the 3-h postprandial period, insulin (time, P  <  0.001) and total @entity165 (time, P  =  0.002) increased, whereas @entity413 (time, P  <  0.001) and high-density lipoprotein @entity165 (time, P  <  0.001) decreased. CONCLUSION: No differential effects of a HF versus a LF isoenergetic meal were seen on postprandial @entity1254 or the gelatinases. @entity1254 increased in response to a high-energy meal independent of treatment, and the gelatinases were lower in response to the HF versus the LF isoenergetic meal, independent of time point. Given the considerable amount of time that @entity1 spend in the postprandial state, additional research is necessary to further understand inflammatory changes in this state.

title: Postprandial XXXX and gelatinase response to a high-fat versus an isoenergetic low-fat meal in lean, healthy @entity1 .

entities_list: @entity1476 :: ('4313', 'Gene') :: ['MMP-2', 'matrix metalloproteinase (MMP)-2']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triacylglycerol', 'triacylglycerols']

entities_list: @entity1254 :: ('9370', 'Gene') :: ['Adiponectin', 'adiponectin']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1254 :: (9370,Gene) :: ['adiponectin']


abstract: OBJECTIVE: Evidence suggests that an acute systemic inflammatory response is invoked after consumption of a high-energy meal. Postprandial regulation of @entity1254 , an adipose tissue-derived, anti-inflammatory hormone, and the gelatinases, @entity1476 and @entity1495 , endopeptidases implicated in a diverse range of inflammatory processes, remain inconclusive. The aim of this study was to assess the postprandial effect of a high-energy (1212  kcal) meal on plasma @entity1254 , @entity1476 and @entity1495 activity, @entity413 , insulin, @entity1674 , total @entity165 , high-density lipoprotein @entity165 , and the differential effects on these parameters depending on whether the test meal was high fat (HF; 46  g fat, 1210  kcal) or isoenergetic and low fat (LF; 15  g fat, 1214  kcal energy). METHODS: Test meals were consumed by 17 lean, healthy @entity1 on two separate occasions with blood samples collected by venipuncture at baseline (0  h) and 1 and 3  h after consumption of each test meal. RESULTS: At baseline, no significant difference was seen in the parameters between the two groups, except for @entity1476 , @entity1495 , and total @entity165 . Over the 3-h postprandial period, no significant differential effect of the HF versus the LF test meal was observed on @entity1254 , @entity1476 , @entity1495 , or on metabolic markers other than @entity1674 , which increased significantly in response to the HF test meal (time  *  treatment, P  =  0.002). When analyzed independent of time, @entity1476 (treatment, P  =  0.006), @entity1495 (treatment, P  =  0.022), and @entity413 (treatment, P  =  0.026) were lower after consumption of the HF meal compared with the LF test meal. When analyzed independent of treatment, @entity1254 increased over the 3-h postprandial period (time, P  =  0.031), but there was no change in @entity1476 or @entity1495 (time, P  =  0.503 and P  =  0.525, respectively). Over the 3-h postprandial period, insulin (time, P  <  0.001) and total @entity165 (time, P  =  0.002) increased, whereas @entity413 (time, P  <  0.001) and high-density lipoprotein @entity165 (time, P  <  0.001) decreased. CONCLUSION: No differential effects of a HF versus a LF isoenergetic meal were seen on postprandial @entity1254 or the gelatinases. @entity1254 increased in response to a high-energy meal independent of treatment, and the gelatinases were lower in response to the HF versus the LF isoenergetic meal, independent of time point. Given the considerable amount of time that @entity1 spend in the postprandial state, additional research is necessary to further understand inflammatory changes in this state.

title: Postprandial @entity1254 and gelatinase response to a high-fat versus an isoenergetic low-fat meal in lean, healthy XXXX .

answer: @entity1 :: (9606,Species) :: ['men']


abstract: Fifty-five @entity1 with superior sulcus syndrome were treated at the UCLA Medical Center and Wadsworth VA Hospital (Los Angeles) between 1956 and 1985. Twenty-eight underwent surgery, six of whom were found unresectable at the time of thoracotomy. Twenty-one of 22 in the resected group received preoperative irradiation. Twenty-seven @entity1 received radiation only. Surgical morbidity was 21%, and there were two in-hospital deaths. Five-year survival for extended resection @entity1 was 34%. The radiation only group had no 5-year survivors. Factors associated with a worse prognosis include positive margins, @entity66 , and vertebral body involvement. The best results for superior @entity5 are obtained by preoperative irradiation followed by en bloc resection of the @entity5 . In the event complete resection is impossible, radiation has a role in palliation of @entity158 with occasional prolonged survival.

title: Factors affecting survival in superior XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'sulcus tumors']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['N2 disease']

answer: @entity5 :: (MESH:D009369,Disease) :: ['sulcus tumors']


abstract: Eleven @entity1 with primary @entity149 (CNS) were treated at the Medical College of Wisconsin Affiliated Hospitals between 1964 and 1984. Three @entity1 had a prior history of immunosuppressive therapy following renal transplantation. All @entity1 had biopsy-proven disease and 10 of the 11 were treated with external radiation therapy. The doses to the @entity5 ranged from 34 to 59.4 Gray (Gy). Actuarial (life-table) survival rate was 82% at 1 year and 43% at 3 years. No recurrence was seen after 13 months. Eighty-six reports totaling 693 cases of primary @entity706 of the CNS were found in the literature. Of these, 308 cases were treated with a combination of surgery and irradiation. Overall survival at 5 years for those @entity1 who received more than 50 Gy compared with less than 50 Gy to the @entity5 was 42.3% versus 12.8% (p less than 0.05). Twenty-one @entity1 survived longer than 5 years. Late relapse was notable, with 10 (47.6%) of 21 @entity5 recurring between 5 and 12.5 years after diagnosis. Based on this review, a minimum of 50 Gy radiation to the @entity5 is recommended. While no statement regarding the efficacy of craniospinal irradiation or chemotherapy can be made in view of the small numbers, the use of craniospinal irradiation and/or systemic chemotherapy should be considered for future trials.

title: Primary XXXX . Results of treatment of 11 cases and review of the literature.

entities_list: @entity149 :: ('MESH:D002493', 'Disease') :: ['malignant lymphoma of the central nervous system']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor', 'tumors']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['malignant lymphoma']

answer: @entity149 :: (MESH:D002493,Disease) :: ['malignant lymphoma of the central nervous system']


abstract: @entity882 ( @entity882 ) is an unusual but serious complication of heparin therapy. Twenty-five @entity1 (13 @entity1 and 12 @entity1 ) had @entity882 and @entity49 1 to 10 days (mean, 6.3 days) after the start of heparin administration. The vessels in the affected extremity had been entered for catheterization, arteriography, or passage of a balloon counterpulsation device in 19 of the 25 @entity1 . In vitro @entity1423 with heparin was seen in all @entity1 . Additional studies were performed to see whether other lots or sources of heparin also produced in vitro aggregation. Four separate lots of beef lung heparin, commercial heparin from porcine intestinal mucosa, and two types of low molecular weight heparin were all highly stimulatory in this system. However, @entity10269 , a heparinoid, did not induce aggregation in any of 13 @entity1 plasmas tested. Inhibition of @entity1423 by @entity117 was also examined. @entity117 abolished in vitro aggregation in 9 of 16 cases and decreased the degree of aggregation from 85% to 55% (p = 0.02) in the remaining seven cases. We conclude that in @entity1 with @entity882 @entity1423 is equally induced by beef lung, porcine intestinal, and some forms of low molecular weight heparin. @entity10269 does not stimulate @entity1423 in plasma from these @entity1 in vitro. Finally, there may be a role for @entity117 in treating @entity1 with @entity882 .

title: XXXX : a serious clinical problem and potential solution.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['HATT', 'thrombocytopenia', 'Heparin-associated thrombocytopenia and thrombosis']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin', 'aspirin']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['arterial or venous thrombosis']

answer: @entity882 :: (MESH:D013921,Disease) :: ['Heparin-associated thrombocytopenia and thrombosis']


abstract: Cordyceps sinensis, a caterpillar entomopathogenic fungus-host larva complex, is a rare medicinal herb found in the Qinghai-Tibetan Plateau and its surrounding @entity2222 areas. The alternation of generations in the life cycle, whatever the fungus or its host insect, requires special growth conditions. However, it is difficult to simulate the growth conditions of @entity2441 , which hinders its artificial cultivation. In this work, the life cycle from the host larva to @entity2441 was observed in an indoor-cultivation laboratory at 4,200 m a.s.l. on Sejila Mountain, Tibet. Comparative examinations between indoor-cultivated and wild @entity2441 demonstrated that the indoor-cultivated @entity2441 preferred to germinate multiple long, slim stromata at diverse positions on dead larvae, including but not limited to their heads. Their @entity844 composition shows a significant difference in the levels of @entity1474 ( @entity5204 ). In indoor-cultivated @entity2441 , @entity5204 constituted 24.59% and 49.43%, respectively, of neutral and polar lipids; meanwhile, in wild @entity2441 , @entity5204 represented 34.34% and 61.25% of neutral and polar lipids, respectively. These observations and @entity844 data suggest that environmental factors, particularly temperature, soil pressure and light intensity, strongly affect the growth of @entity2441 . Our new findings may provide important information for improving techniques for the large-scale artificial cultivation of @entity2441 .

title: Morphological Observations and XXXX Composition of Indoor-Cultivated Cordyceps sinensis at a High-Altitude Laboratory on Sejila Mountain, Tibet.

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity2222 :: ('MESH:C535833', 'Disease') :: ['high-altitude']

entities_list: @entity1474 :: ('MESH:D005231', 'Chemical') :: ['polyunsaturated fatty acids']

answer: @entity844 :: (CHEBI:35366,Chemical) :: ['Fatty Acid']


abstract: BACKGROUND: @entity725 ( @entity725 ) is the most common form of @entity726 with a genetic predisposition. The relationship between polymorphisms in @entity29714 or @entity2204 promoter region and @entity725 has been addressed in many case-control studies, but the published results were not consistent. METHODS: A meta-analysis assessing the association between five single nucleotide polymorphisms (SNPs) (in @entity29714 promoter: @entity72035 and @entity72036 ; in @entity2204 promoter: @entity20448 , @entity72037 and @entity72038 ) and the risk of @entity725 was performed based on included studies from literature research. In fixed effect model or random effect model, the Mantel-Haenszel (M-H) pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the genetic association. Stratification analysis was also conducted to test the association within Asian or Caucasian populations. RESULTS: Twenty five case-control studies within multiple populations were identified and no publish bias was observed. Significant association was detected between @entity725 risk and @entity29714 @entity72036 in Caucasian (GA+AA vs. GG, OR=0.587, 95% CI=0.437-0.788, P < 0.001). For other SNPs and in other ethnic populations, no statistic evidence was detected for significant association between them and the development of @entity725 . CONCLUSIONS: This meta-analysis suggested a genetic association between one of @entity29714 polymorphism ( @entity72036 ) and the risk of @entity725 only in Caucasian population. The significant heterogeneity for this locus might imply the different @entity725 genetic basis among different populations.

title: Association of XXXX and @entity2204 promoter polymorphisms and primary open-angle glaucoma: a meta-analysis.

entities_list: @entity725 :: ('MESH:C562750', 'Disease') :: ['POAG', 'Primary open-angle glaucoma']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

answer: @entity29714 :: (4653,Gene) :: ['MYOC']


abstract: BACKGROUND: @entity725 ( @entity725 ) is the most common form of @entity726 with a genetic predisposition. The relationship between polymorphisms in @entity29714 or @entity2204 promoter region and @entity725 has been addressed in many case-control studies, but the published results were not consistent. METHODS: A meta-analysis assessing the association between five single nucleotide polymorphisms (SNPs) (in @entity29714 promoter: @entity72035 and @entity72036 ; in @entity2204 promoter: @entity20448 , @entity72037 and @entity72038 ) and the risk of @entity725 was performed based on included studies from literature research. In fixed effect model or random effect model, the Mantel-Haenszel (M-H) pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the genetic association. Stratification analysis was also conducted to test the association within Asian or Caucasian populations. RESULTS: Twenty five case-control studies within multiple populations were identified and no publish bias was observed. Significant association was detected between @entity725 risk and @entity29714 @entity72036 in Caucasian (GA+AA vs. GG, OR=0.587, 95% CI=0.437-0.788, P < 0.001). For other SNPs and in other ethnic populations, no statistic evidence was detected for significant association between them and the development of @entity725 . CONCLUSIONS: This meta-analysis suggested a genetic association between one of @entity29714 polymorphism ( @entity72036 ) and the risk of @entity725 only in Caucasian population. The significant heterogeneity for this locus might imply the different @entity725 genetic basis among different populations.

title: Association of @entity29714 and XXXX promoter polymorphisms and primary open-angle glaucoma: a meta-analysis.

answer: @entity2204 :: (348,Gene) :: ['APOE']


abstract: This study is to explore and evaluate the efficacy and safety of local thrombolytic therapy in superior sagittal sinus in @entity1 with severe @entity50 during puerperium, as well as the efficacy and safety of anti-platelet aggregation treatment for preventing recurrence. Twelve @entity1 during postpartum period with @entity50 were received local thrombolytic therapy by placing a micro-catheter at the distal end of superior sagittal sinus from January 2008 to December 2013. All the @entity1 accepted mechanical @entity715 maceration before local intrasinus thrombolytic therapy, and were treated with low molecular weight heparin in the acute phase. After local thrombolytic therapy, anti-platelet aggregation treatment was performed for 6 months. Follow-up data included lumber puncture, fundus examination and magnetic resonance venography (MRV) once per half year for 6-70 months. At discharge, the intracranial pressure of 12 @entity1 reduced to below 200 mmH2O. DSA or MRV confirmed that superior sagittal sinus of 9 @entity1 were smooth. The cortex venous and deep venous were recovered to normal. Superior sagittal sinus of 3 @entity1 recanalized partly. Cortex venous and deep venous was compensated. The follow-up study indicated that no @entity715 and new @entity16 occurred among all @entity1 . Local thrombolytic treatment is safe and effective in @entity1 with severe @entity50 during puerperium. The collateral circulation compensation is the main recovery factor. And it is also safe and effective for anti-platelet aggregation treatment to prevent recurrence of @entity50 .

title: Local thrombolytic therapy in severe XXXX during puerperium.

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus', 'thrombosis']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological symptoms']

entities_list: @entity50 :: ('MESH:D012851', 'Disease') :: ['cerebral venous sinus thrombosis']

answer: @entity50 :: (MESH:D012851,Disease) :: ['cerebral venous sinus thrombosis']


abstract: Painful peripheral neuropathy due to the antiretroviral therapy used to treat @entity645 is one of the most prevalent side effects occurring in at least 30% of @entity1 living with this infection. We have evaluated the electrophysiological and behavioral effects of @entity14027 and ddC on peripheral large and small nerve fibers in male @entity35 treated with @entity14027 (Sprague-Dawley, 50 mg/kg, twice within 1 week), ddC ( @entity35 , 50 mg/kg, 3 times per week for 3 weeks), or vehicle. The effect of the interventions was assessed using behavioral measures of mechanical sensitivity, conventional nerve conduction studies, and microneurographic single nerve @entity7183 recordings. To mimic as much as possible the @entity1 clinical condition, all treated animals were included in the study. No statistically significant differences were observed in behavioral parameters of mechanical sensitivity. Nerve conduction studies did not reveal any significant change in the @entity7725 -treated group. In contrast, we observed electrophysiological evidence of significant demyelinating neuropathy 1 week after the start of @entity14027 treatment. Additionally, spontaneous activity in mechanoinsensitive C-nociceptors was observed in both drug-treated groups. No relationship could be established between measures of spontaneous activity in C-nociceptors and the results of the behavioral tests. Our results show that both models of antiretroviral-induced neuropathy differ in their effects on peripheral nerves. However, both groups present abnormal spontaneous activity in mechanoinsensitive C-nociceptors that can be used as a model for pharmacological intervention.

title: Behavioral and electrophysiological abnormalities in two XXXX models of antiretroviral drug-induced neuropathy.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: BACKGROUND: Alerts embedded in electronic health records (EHRs) are designed to improve processes at the point of care. OBJECTIVE: The aim of this study was to determine if an EHR alert-at @entity341 ( @entity341 ) triage-increases the @entity341 triage nurse's utilization of triage protocols. METHODS: @entity341 triage nurses were randomized to receive either a passive EHR alert or no intervention for @entity1 with the following complaints: minor @entity130 with extremity injuries or female @entity1 with @entity490 . The EHR alert notified the nurse that the @entity1 was eligible for diagnostic testing: radiographs for @entity1 with injured extremities or urinalysis for female @entity1 with @entity490 . RESULTS: Twenty-eight nurses triaged 20,410 @entity1 in the 6 months before the intervention and 19,157 in the 6 months after the intervention. Before the intervention, the urinalysis protocol was implemented in 101/624 (16.2%) @entity1 triaged by the intervention group and 116/711 (16.3%) triaged by the control group. After the intervention, the urinalysis protocol was implemented in 146/530 (27.6%) @entity1 triaged by the intervention group and 174/679 (25.6%) triaged by the control group. Before the intervention, the radiograph protocol was implemented in 58/774 (7.5%) @entity1 triaged by the intervention group and 45/684 (6.6%) triaged by the control group. After the intervention, the radiograph protocol was implemented in 78/614 (12.7%) @entity1 triaged by the intervention group and 79/609 (13.0%) triaged by the control group. CONCLUSION: The use of a passive EHR alert to promote @entity341 triage protocols showed little benefit. Before the widespread implementation of EHR alerts for @entity1 care, rigorous studies are required to determine the best alert methods and the impacts of such interventions.

title: Electronic alerts for triage protocol compliance among XXXX triage nurses: a randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

answer: @entity341 :: (MESH:D004630,Disease) :: ['emergency department']


abstract: UNASSIGNED: OBJECT Symptomatic pediatric @entity1645 ( @entity1645 ) is most often treated with @entity6804 ( @entity6804 ), but controversy exists over whether the dura needs to be opened during @entity6804 . While dural opening as a part of @entity6804 has been suggested to result in a higher rate of resolution of @entity1109 , it has also been shown to lead to more frequent complications. In this paper, the authors present the largest reported series of outcomes after @entity6804 without dural opening surgery, as well as identify risk factors for recurrence. METHODS The authors performed a retrospective review of 156 consecutive pediatric @entity1 in whom the senior authors performed @entity6804 without dural opening from 2003 to 2013. @entity1 demographics, clinical symptoms and signs, radiographic findings, intraoperative ultrasound results, and neuromonitoring findings were reviewed. Univariate and multivariate regression analyses were performed to determine risk factors for recurrence of symptoms and the need for reoperation. RESULTS Over 90% of @entity1 had a good clinical outcome, with improvement or resolution of their symptoms at last follow-up (mean 32 months). There were no major complications. The mean length of hospital stay was 2.0 days. In a multivariate regression model, partial @entity3627 laminectomy was an independent risk factor associated with reoperation (p = 0.037). Motor weakness on presentation was also associated with reoperation but only with trend-level significance (p = 0.075). No @entity1 with < 8 mm of @entity3976 required reoperation. CONCLUSIONS The vast majority (> 90%) of @entity1 with symptomatic @entity1645 will have improvement or resolution of symptoms after a @entity6804 without dural opening. A non-dural opening approach avoids major complications. While no @entity1 with @entity3976 < 8 mm required reoperation, @entity1 with @entity3976 at or below @entity3627 have a higher risk for failure when this approach is used.

title: Outcomes after suboccipital decompression without dural opening in @entity1 with XXXX .

entities_list: @entity6804 :: ('MESH:D015192', 'Disease') :: ['posterior fossa decompression', 'PFD']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'Patient']

entities_list: @entity3976 :: ('MESH:D004677', 'Disease') :: ['tonsillar herniation']

entities_list: @entity1645 :: ('MESH:D001139', 'Disease') :: ['Chiari malformation Type I', 'CM-I']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['CM symptoms']

answer: @entity1645 :: (MESH:D001139,Disease) :: ['Chiari malformation Type I']


abstract: UNASSIGNED: OBJECT Symptomatic pediatric @entity1645 ( @entity1645 ) is most often treated with @entity6804 ( @entity6804 ), but controversy exists over whether the dura needs to be opened during @entity6804 . While dural opening as a part of @entity6804 has been suggested to result in a higher rate of resolution of @entity1109 , it has also been shown to lead to more frequent complications. In this paper, the authors present the largest reported series of outcomes after @entity6804 without dural opening surgery, as well as identify risk factors for recurrence. METHODS The authors performed a retrospective review of 156 consecutive pediatric @entity1 in whom the senior authors performed @entity6804 without dural opening from 2003 to 2013. @entity1 demographics, clinical symptoms and signs, radiographic findings, intraoperative ultrasound results, and neuromonitoring findings were reviewed. Univariate and multivariate regression analyses were performed to determine risk factors for recurrence of symptoms and the need for reoperation. RESULTS Over 90% of @entity1 had a good clinical outcome, with improvement or resolution of their symptoms at last follow-up (mean 32 months). There were no major complications. The mean length of hospital stay was 2.0 days. In a multivariate regression model, partial @entity3627 laminectomy was an independent risk factor associated with reoperation (p = 0.037). Motor weakness on presentation was also associated with reoperation but only with trend-level significance (p = 0.075). No @entity1 with < 8 mm of @entity3976 required reoperation. CONCLUSIONS The vast majority (> 90%) of @entity1 with symptomatic @entity1645 will have improvement or resolution of symptoms after a @entity6804 without dural opening. A non-dural opening approach avoids major complications. While no @entity1 with @entity3976 < 8 mm required reoperation, @entity1 with @entity3976 at or below @entity3627 have a higher risk for failure when this approach is used.

title: Outcomes after suboccipital decompression without dural opening in XXXX with @entity1645 .

answer: @entity1 :: (9606,Species) :: ['children']


abstract: UNASSIGNED: This study evaluated the effects of electroacupuncture (EA) on endothelial function and endothelial progenitor cells (EPC) in @entity1 with @entity385 . In a randomized, placebo-controlled, crossover study, 20 @entity1 with @entity385 were randomized into two treatment groups: EA or placebo. Before and after each intervention, pulse amplitude tonometry (PAT) was used to assess endothelial function and peripheral blood was analyzed for the number of EPCs. Circulating EPCs were quantified by flow cytometry as @entity1195 (low) @entity2280 (+) KDR2(+) cells. Plasma @entity7 ( @entity7 ) and @entity688 levels were measured. Seven days later, crossover was performed on each group, with each group receiving the other treatment using the same protocol. The PAT @entity450 ratio ranged from 1.57  0.41 to 2.04  0.51 after EA, representing a significant improvement (p=0.002); however, there was no improvement in the placebo group (p=0.48). Circulating EPCs, as measured by flow cytometry, increased to 110.6    74.3/100ul in the EA group (p=0.001) but did not change in the placebo group (45.9    35.3/100ul, p=0.08). The increases in the number  of EPCs and the PAT ratio after treatment were correlated (r=0.78, p<0.001). Plasma @entity7 levels increased with EA compared to baseline (261.2  34.0 vs. 334.9  80.5 pg/mL, p=0.003). The number of circulating EPCs was positively correlated with plasma levels of @entity7 (r=0.50, p=0.02). In conclusion, EA induced improvement of EPC levels and the PAT ratio in @entity1 with @entity385 . This article is protected by copyright. All rights reserved.

title: Effects of Electroacupuncture on Endothelial Function and Circulating Endothelial Progenitor Cells in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['cerebral infarction']

answer: @entity385 :: (MESH:D002544,Disease) :: ['Cerebral Infarction']


abstract: UNASSIGNED: This study evaluated the effects of electroacupuncture (EA) on endothelial function and endothelial progenitor cells (EPC) in @entity1 with @entity385 . In a randomized, placebo-controlled, crossover study, 20 @entity1 with @entity385 were randomized into two treatment groups: EA or placebo. Before and after each intervention, pulse amplitude tonometry (PAT) was used to assess endothelial function and peripheral blood was analyzed for the number of EPCs. Circulating EPCs were quantified by flow cytometry as @entity1195 (low) @entity2280 (+) KDR2(+) cells. Plasma @entity7 ( @entity7 ) and @entity688 levels were measured. Seven days later, crossover was performed on each group, with each group receiving the other treatment using the same protocol. The PAT @entity450 ratio ranged from 1.57  0.41 to 2.04  0.51 after EA, representing a significant improvement (p=0.002); however, there was no improvement in the placebo group (p=0.48). Circulating EPCs, as measured by flow cytometry, increased to 110.6    74.3/100ul in the EA group (p=0.001) but did not change in the placebo group (45.9    35.3/100ul, p=0.08). The increases in the number  of EPCs and the PAT ratio after treatment were correlated (r=0.78, p<0.001). Plasma @entity7 levels increased with EA compared to baseline (261.2  34.0 vs. 334.9  80.5 pg/mL, p=0.003). The number of circulating EPCs was positively correlated with plasma levels of @entity7 (r=0.50, p=0.02). In conclusion, EA induced improvement of EPC levels and the PAT ratio in @entity1 with @entity385 . This article is protected by copyright. All rights reserved.

title: Effects of Electroacupuncture on Endothelial Function and Circulating Endothelial Progenitor Cells in XXXX with @entity385 .

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: The present study demonstrates a major remodeling of the nuclear envelope and its underlying lamina during @entity291 preimplantation development. Up to the onset of major embryonic genome activation (MGA) at the 8-cell stage nuclei showed a non-uniform distribution of nuclear pore complexes (NPCs). NPCs were exclusively present at sites where DNA contacted the nuclear lamina. Extended regions of the lamina, which were not contacted by DNA, lacked NPCs. In post-MGA nuclei the whole lamina was contacted rather uniformly by DNA. Accordingly, NPCs became uniformly distributed throughout the entire nuclear envelope. These findings shed new light on the conditions which control the integration of NPCs into the nuclear envelope. The switch from maternal to embryonic production of mRNAs was accompanied by @entity3473 covered with NPCs, which may serve the increased demands of mRNA export and protein import. Other invaginations, as well as interior nuclear segments and vesicles without contact to the nuclear envelope, were exclusively positive for lamin B. Since the abundance of these invaginations and vesicles increased in concert with a massive nuclear volume reduction, we suggest that they reflect a mechanism for fitting the nuclear envelope and its lamina to a shrinking nuclear size during @entity291 preimplantation development. In addition, a deposit of extranuclear clusters of @entity68562 (a marker for NPCs) without associated lamin B was frequently observed from the zygote stage up to MGA. Corresponding RNA-Seq data revealed deposits of spliced, maternally provided @entity68562 mRNA and little unspliced, newly synthesized RNA prior to MGA, which increased strongly at the initiation of embryonic expression of @entity68562 at MGA.

title: Remodeling of the Nuclear Envelope and Lamina during XXXX Preimplantation Development and Its Functional Implications.

entities_list: @entity3473 :: ('MESH:D007443', 'Disease') :: ['multiple invaginations']

answer: @entity291 :: (9913,Species) :: ['Bovine']


abstract: Three hundred eighty-seven pregnancies (295 @entity1 ) complicated by maternal @entity299 , managed at the National Maternity Hospital, Dublin, Ireland, during the years 1969 to 1978, were reviewed. The incidence was 0.5%. Three hundred twenty-three (83.5%) were of rheumatic origin, 52 (13.4%) were congenital, and the remaining 12 (3.1%) were a miscellaneous group and included cases of @entity3618 and @entity453 . There were two maternal @entity204 --one from @entity299 and one from postpartum suicide, unrelated to mild @entity6331 . The perinatal mortality rate was 3.3%. Five pregnancies (three @entity1 ) were complicated by surgically uncorrected @entity299 . One of the maternal @entity204 and three of the perinatal @entity204 occurred in this group. There were 38 episodes of @entity712 (38 @entity1 ) in cases of @entity6331 . The New York Heart Association grading was grade 1 in 15 (39%) of these before the onset of failure. Prophylactic antibiotics were not used and @entity884 did not occur. Therapeutic abortion was not practiced and a conservative approach was adopted in obstetric intervention and in all drug therapy.

title: Pregnancy complicated by maternal XXXX at the National Maternity Hospital, Dublin, Ireland, 1969 to 1978.

entities_list: @entity6331 :: ('MESH:D012214', 'Disease') :: ['rheumatic heart disease']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure']

entities_list: @entity3618 :: ('MESH:D011660', 'Disease') :: ['cor pulmonale']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cyanotic congenital heart disease', 'heart disease', 'congenital heart disease']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['infective endocarditis']

answer: @entity299 :: (MESH:D006331,Disease) :: ['heart disease']


abstract: UNASSIGNED: In Y-stenting, stabilization of the first stent may be problematic as in some cases it migrates during second stent insertion. This report evaluates the safety and effectiveness of the technique and presents the long-term results of hybrid, Y-configured, dual stent-assisted coil embolization in the treatment of wide-necked bifurcation @entity439 . We retrospectively evaluated the @entity1 treated endovascularly due to @entity438 . Twenty @entity1 treated with hybrid Y-stent-assisted coil embolization were enrolled in the study. In hybrid stenting, an open-cell intracranial stent (Neuroform) was used as a first stent to prevent stent migration. A closed-cell stent (Enterprise or Acclino) was used as a second stent and the @entity439 was embolized with coils between the stent struts. In all @entity1 , hybrid Y-stenting and coil embolization were accomplished successfully. No stent migration occurred. Clinically, neither symptomatic @entity16 nor @entity204 was seen. Of 20 wide-necked bifurcation @entity439 , nine were at the basilar tip, while seven were at the middle cerebral artery and three at the anterior communicating artery. In one @entity1 , the @entity439 was at the A2-3 junction of the anterior cerebral artery. One of the @entity1 had a @entity510 . The mean angiographic follow-up was 25.6 months. No in-stent @entity850 was seen in any of the @entity1 and recanalization in only one. Hybrid, Y-configured, dual stent-assisted coil embolization is a safe and effective method in the treatment of wide-necked bifurcation @entity439 to prevent stent migration and @entity439 recanalization, and is a viable alternative to microsurgery.

title: Hybrid, Y-configured, dual stent-assisted coil embolization in the treatment of wide-necked bifurcation XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhage']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic complication']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysm']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['cerebral aneurysms']

answer: @entity439 :: (MESH:D000783,Disease) :: ['aneurysms']


abstract: OBJECTIVES: To determine whether the @entity5 necrosis factor a inhibitor etanercept is well tolerated and obtain preliminary data on its safety in @entity195 . METHODS: In a double-blind study, @entity1 with mild to moderate @entity195 were randomized (1:1) to subcutaneous etanercept (50 mg) once weekly or identical placebo over a 24-week period. Tolerability and safety of this medication was recorded including secondary outcomes of cognition, global function, behavior, and systemic cytokine levels at baseline, 12 weeks, 24 weeks, and following a 4-week washout period. This trial is registered with EudraCT (2009-013400-31) and ClinicalTrials.gov (NCT01068353). RESULTS: Forty-one @entity1 (mean age 72.4 years; 61% @entity1 ) were randomized to etanercept (n = 20) or placebo (n = 21). Etanercept was well tolerated; 90% of @entity1 (18/20) completed the study compared with 71% (15/21) in the placebo group. Although @entity281 were more common in the etanercept group, there were no serious adverse events or new safety concerns. While there were some interesting trends that favored etanercept, there were no statistically significant changes in cognition, behavior, or global function. CONCLUSIONS: This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in this small group of @entity1 with @entity195 , but a larger more heterogeneous group needs to be tested before recommending its use for broader groups of @entity1 . CLASSIFICATION OF EVIDENCE: This study shows Class I evidence that weekly subcutaneous etanercept is well tolerated in @entity195 .

title: Etanercept in XXXX : A randomized, placebo-controlled, double-blind, phase 2 trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'men']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['Alzheimer disease dementia']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer disease']


abstract: BACKGROUND: @entity2976 ( @entity2976 ) is an excessive fibrotic response of the peritoneum that may occur after long-term @entity298 ( @entity298 ). The underlying pathophysiology is poorly understood, but involvement of peritoneal inflammatory T helper 1 cells may be pivotal. METHODS: Soluble @entity2902 (sCD25) concentration was measured as a marker for T-cell activation in serum and ascites from @entity2976 @entity1 and various control @entity1 groups. Peritoneal biopsies were stained for the presence of T cells, and T cells isolated from ascites of @entity2976 @entity1 were characterized in detail for differentiation status and cytokine expression. RESULTS: Serum sCD25 concentrations are significantly and specifically increased in @entity2976 @entity1 compared with haemodialysis, @entity298 and predialysis @entity1 . Peritoneal effluent of stable @entity298 @entity1 contains very low levels of sCD25, while sCD25 levels in ascites of @entity2976 @entity1 are high and indicative of local production. In the years preceding the diagnosis of @entity2976 , the serum sCD25 concentrations increased while remaining at stable levels in control @entity298 @entity1 . The peritoneum and ascites of @entity2976 @entity1 showed a significant influx of T cells with relatively increased numbers of @entity404 (+) T cells. These T cells were fully differentiated and displayed a T helper 1 cell type with a pro-inflammatory cytokine profile. CONCLUSIONS: Increased serum sCD25 concentrations and peritoneal lymphocytosis in @entity2976 @entity1 indicate the involvement of activated T cells in the pathophysiology of excessive @entity82 .

title: XXXX is associated with T-cell activation.

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity2976 :: ('MESH:D056627', 'Disease') :: ['Encapsulating peritoneal sclerosis', 'EPS']

entities_list: @entity2902 :: ('3559', 'Gene') :: ['interleukin-2 receptor alpha']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD']

answer: @entity2976 :: (MESH:D056627,Disease) :: ['Encapsulating peritoneal sclerosis']


abstract: INTRODUCTION: We hypothesized that treating @entity174 with cast only or closed reduction and cast is associated with high malunion risk and that the risk is higher in @entity1 with low @entity79 ( @entity79 ). MATERIALS AND METHODS: We prospectively studied 130 @entity1 aged 40  years or older with @entity174 treated with cast only (87 @entity1 ) or closed reduction and cast (43 @entity1 ). Radiographs were obtained before treatment, after reduction (in the closed reduction group), and at 1  year. We measured calcaneal @entity79 with DXA scanner and calculated T scores. We calculated radiological changes from baseline (initial radiographs in cast only and post-reduction radiographs in closed reduction @entity1 ) to 1  year. We assessed the relationship between @entity79 status (normal, @entity2331 or @entity170 ) and baseline-to-1-year worsening in volar tilt, ulnar variance, and radial inclination with analysis of covariance adjusting for baseline radiological values. We used receiver operating characteristic (ROC) analysis to determine the ability of T scores to distinguish @entity1 with severe malunion (dorsal tilt >25   and/or ulnar variance >= 5  mm) from those with less severe or no malunion. RESULTS: In both treatment groups, baseline radiological variables had deteriorated at 1  year, more in the closed reduction group. Compared to @entity1 with normal @entity79 , those with @entity170 had significantly greater worsening in volar tilt and radial inclination but did not differ in ulnar variance worsening. Severe malunion was found in 34 @entity174 (26  %, 15 in cast only group); T scores had a modest ability in distinguishing severe malunion (area under ROC curve 0.67, 95  % CI 0.56-0.78, p  =  0.003). CONCLUSIONS: Closed reduction and cast is not an effective treatment for @entity174 if radiological graphic outcomes are considered. There is a higher risk of malunion involving dorsal and radial tilt in @entity1 with @entity170 . Calcaneal @entity79 measurement may have some benefit in predicting the risk of severe malunion.

title: Cast-treated XXXX : a prospective cohort study of radiological outcomes and their association with impaired calcaneal @entity79 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'distal radius fractures']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD']

entities_list: @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia']

answer: @entity174 :: (MESH:D050723,Disease) :: ['distal radius fractures']


abstract: INTRODUCTION: We hypothesized that treating @entity174 with cast only or closed reduction and cast is associated with high malunion risk and that the risk is higher in @entity1 with low @entity79 ( @entity79 ). MATERIALS AND METHODS: We prospectively studied 130 @entity1 aged 40  years or older with @entity174 treated with cast only (87 @entity1 ) or closed reduction and cast (43 @entity1 ). Radiographs were obtained before treatment, after reduction (in the closed reduction group), and at 1  year. We measured calcaneal @entity79 with DXA scanner and calculated T scores. We calculated radiological changes from baseline (initial radiographs in cast only and post-reduction radiographs in closed reduction @entity1 ) to 1  year. We assessed the relationship between @entity79 status (normal, @entity2331 or @entity170 ) and baseline-to-1-year worsening in volar tilt, ulnar variance, and radial inclination with analysis of covariance adjusting for baseline radiological values. We used receiver operating characteristic (ROC) analysis to determine the ability of T scores to distinguish @entity1 with severe malunion (dorsal tilt >25   and/or ulnar variance >= 5  mm) from those with less severe or no malunion. RESULTS: In both treatment groups, baseline radiological variables had deteriorated at 1  year, more in the closed reduction group. Compared to @entity1 with normal @entity79 , those with @entity170 had significantly greater worsening in volar tilt and radial inclination but did not differ in ulnar variance worsening. Severe malunion was found in 34 @entity174 (26  %, 15 in cast only group); T scores had a modest ability in distinguishing severe malunion (area under ROC curve 0.67, 95  % CI 0.56-0.78, p  =  0.003). CONCLUSIONS: Closed reduction and cast is not an effective treatment for @entity174 if radiological graphic outcomes are considered. There is a higher risk of malunion involving dorsal and radial tilt in @entity1 with @entity170 . Calcaneal @entity79 measurement may have some benefit in predicting the risk of severe malunion.

title: Cast-treated @entity174 : a prospective cohort study of radiological outcomes and their association with impaired calcaneal XXXX .

answer: @entity79 :: (MESH:D001847,Disease) :: ['bone mineral density']


abstract: AIMS: Left atrial appendage (LAA) is the source of thrombi in up to 90% of @entity1 with non-valvular @entity955 ( @entity955 ). Catheter ablation (CA) is an effective treatment for symptomatic @entity955 and, in selected cases, LAA occlusion devices have been introduced as an alternative to oral anticoagulants (OACs). The safety and feasibility of combining CA and percutaneous LAA closure (LAAC) are unknown. METHODS AND RESULTS: @entity1 with symptomatic drug-refractory @entity955 , CHADS2 score of >= 1, and CHA2DS2-VASc score >= 2 were included. Catheter ablation consisted in pulmonary vein isolation with or without roof line with radiofrequency and LAA was occluded with the Watchman or @entity299 ( @entity299 ) devices guided by angiography and transoesophageal echocardiography. A total of 35 @entity1 were included (71% male; 70 years). Median score was 3 on both CHA2DS2-VASc and HAS-BLED, 9% had prior @entity64 under OAC, and 48% had @entity548 complications. Successful CA and device implantation were achieved in 97% of cases. The Watchman device was used in 29 @entity1 and @entity299 in 6 @entity1 . Periprocedural complications included three cases of @entity2293 . At 3 months, all @entity1 met the criteria for successful sealing of the LAA. After a mean follow-up of 13 months (3-75), 78% of @entity1 were free of @entity943 recurrences and OAC was withheld in 97% of @entity1 . CONCLUSIONS: The combination of CA and percutaneous LAAC in a single procedure is technically feasible in @entity1 with symptomatic drug-refractory @entity955 , high risk of @entity64 , and contraindications to OACs, although it is associated with a significant risk of major complications.

title: Combined catheter ablation and left XXXX as a hybrid procedure for the treatment of @entity955 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity2293 :: ('MESH:D002305', 'Disease') :: ['cardiac tamponade']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['Amplatzer Cardiac Plug', 'ACP']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial appendage closure']


abstract: AIMS: Left atrial appendage (LAA) is the source of thrombi in up to 90% of @entity1 with non-valvular @entity955 ( @entity955 ). Catheter ablation (CA) is an effective treatment for symptomatic @entity955 and, in selected cases, LAA occlusion devices have been introduced as an alternative to oral anticoagulants (OACs). The safety and feasibility of combining CA and percutaneous LAA closure (LAAC) are unknown. METHODS AND RESULTS: @entity1 with symptomatic drug-refractory @entity955 , CHADS2 score of >= 1, and CHA2DS2-VASc score >= 2 were included. Catheter ablation consisted in pulmonary vein isolation with or without roof line with radiofrequency and LAA was occluded with the Watchman or @entity299 ( @entity299 ) devices guided by angiography and transoesophageal echocardiography. A total of 35 @entity1 were included (71% male; 70 years). Median score was 3 on both CHA2DS2-VASc and HAS-BLED, 9% had prior @entity64 under OAC, and 48% had @entity548 complications. Successful CA and device implantation were achieved in 97% of cases. The Watchman device was used in 29 @entity1 and @entity299 in 6 @entity1 . Periprocedural complications included three cases of @entity2293 . At 3 months, all @entity1 met the criteria for successful sealing of the LAA. After a mean follow-up of 13 months (3-75), 78% of @entity1 were free of @entity943 recurrences and OAC was withheld in 97% of @entity1 . CONCLUSIONS: The combination of CA and percutaneous LAAC in a single procedure is technically feasible in @entity1 with symptomatic drug-refractory @entity955 , high risk of @entity64 , and contraindications to OACs, although it is associated with a significant risk of major complications.

title: Combined catheter ablation and left @entity955 as a hybrid procedure for the treatment of XXXX .

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']


abstract: OBJECTIVE: Whereas uncomplicated acute type B aortic dissections are often medically managed with good outcomes, a subset develop subacute or chronic @entity384 . We hypothesized that @entity5173 ( @entity5173 ) simulations may be useful in identifying @entity1 at risk for this complication. METHODS: @entity1 with acute type B dissection complicated by rapidly expanding @entity449 (N  = 7) were compared with @entity1 with stable aortic diameters (N  = 7). Three-dimensional @entity1 -specific dissection geometries were generated from computed tomography angiography and used in @entity5173 simulations of pulsatile blood flow. Hemodynamic parameters including false lumen flow and wall shear stress were compared. RESULTS: @entity1 with rapid @entity439 had a growth rate of 5.3     2.7  mm/mo compared with those with stable aortic diameters, who had rates of 0.2     0.02  mm/mo. Groups did not differ in initial aortic diameter (36.1     2.9 vs 34.4     3.6  mm; P  = .122) or false lumen size (22.6     2.9 vs 20.2     4.5  mm; P  = .224). In @entity1 with rapidly expanding @entity439 , a greater percentage of total flow passed through the false lumen (78.3%     9.3% vs 56.3%     11.8%; P  = .016). The time-averaged wall shear stress on the aortic wall was also significantly higher (12.6     3.7 vs 7.4     2.8  Pa; P  = .028). CONCLUSIONS: Hemodynamic parameters derived from @entity5173 simulations of acute type B aortic dissections were significantly different in dissections complicated by @entity439 formation. Thus, @entity5173 may assist in predicting which @entity1 may benefit from early stent grafting.

title: Use of @entity5173 studies in predicting XXXX of acute type B  aortic dissections.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity449 :: ('MESH:D001014', 'Disease') :: ['aortic aneurysms']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['aneurysmal dilation']

entities_list: @entity5173 :: ('MESH:D065634', 'Disease') :: ['CFD', 'computational fluid dynamics']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysmal degeneration', 'aneurysm']

answer: @entity439 :: (MESH:D000783,Disease) :: ['aneurysmal degeneration']


abstract: OBJECTIVE: Whereas uncomplicated acute type B aortic dissections are often medically managed with good outcomes, a subset develop subacute or chronic @entity384 . We hypothesized that @entity5173 ( @entity5173 ) simulations may be useful in identifying @entity1 at risk for this complication. METHODS: @entity1 with acute type B dissection complicated by rapidly expanding @entity449 (N  = 7) were compared with @entity1 with stable aortic diameters (N  = 7). Three-dimensional @entity1 -specific dissection geometries were generated from computed tomography angiography and used in @entity5173 simulations of pulsatile blood flow. Hemodynamic parameters including false lumen flow and wall shear stress were compared. RESULTS: @entity1 with rapid @entity439 had a growth rate of 5.3     2.7  mm/mo compared with those with stable aortic diameters, who had rates of 0.2     0.02  mm/mo. Groups did not differ in initial aortic diameter (36.1     2.9 vs 34.4     3.6  mm; P  = .122) or false lumen size (22.6     2.9 vs 20.2     4.5  mm; P  = .224). In @entity1 with rapidly expanding @entity439 , a greater percentage of total flow passed through the false lumen (78.3%     9.3% vs 56.3%     11.8%; P  = .016). The time-averaged wall shear stress on the aortic wall was also significantly higher (12.6     3.7 vs 7.4     2.8  Pa; P  = .028). CONCLUSIONS: Hemodynamic parameters derived from @entity5173 simulations of acute type B aortic dissections were significantly different in dissections complicated by @entity439 formation. Thus, @entity5173 may assist in predicting which @entity1 may benefit from early stent grafting.

title: Use of XXXX studies in predicting @entity439 of acute type B  aortic dissections.

answer: @entity5173 :: (MESH:D065634,Disease) :: ['computational fluid dynamics']


abstract: From 1972-1982 149 pathological @entity174 in 91 @entity1 were treated. 134 of these were caused by @entity5 . With 78% metastases were the most common cause for @entity174 . 59% of the @entity1 were @entity1 . The most frequent @entity174 localisation was the femur followed by ribs and humerus. 62% of the @entity174 but 100% of the leg @entity174 were treated operatively. The best functional results were achieved after compound osteo-synthesis. The mean survival time of the @entity1 was 10.7 months. The one year survival rate was 24.6% and the two year survival rate was 9.2%. The best survival rates were observed in @entity1 , @entity1 with @entity0 metastases, femur shaft- or subtrochanteric @entity174 . The lowest survival rate was found in male @entity1 , @entity1 with unknown primary @entity5 and @entity2249 .

title: [Functional results following conservative and surgical therapy of pathologic XXXX in @entity5 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity2249 :: ('MESH:D005265', 'Disease') :: ['femur neck fractures']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant disease', 'tumour']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fractures']


abstract: From 1972-1982 149 pathological @entity174 in 91 @entity1 were treated. 134 of these were caused by @entity5 . With 78% metastases were the most common cause for @entity174 . 59% of the @entity1 were @entity1 . The most frequent @entity174 localisation was the femur followed by ribs and humerus. 62% of the @entity174 but 100% of the leg @entity174 were treated operatively. The best functional results were achieved after compound osteo-synthesis. The mean survival time of the @entity1 was 10.7 months. The one year survival rate was 24.6% and the two year survival rate was 9.2%. The best survival rates were observed in @entity1 , @entity1 with @entity0 metastases, femur shaft- or subtrochanteric @entity174 . The lowest survival rate was found in male @entity1 , @entity1 with unknown primary @entity5 and @entity2249 .

title: [Functional results following conservative and surgical therapy of pathologic @entity174 in XXXX ].

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignant diseases']


abstract: PURPOSE: To investigate the efficacy and technical applicability of cavitron ultrasonic surgical aspirator (CUSA)-driven zero- @entity63 open partial nephrectomy in @entity1 with @entity703 . MATERIALS AND METHODS: We prospectively collected data of 13 consecutive @entity1 , who underwent open partial nephrectomy under non-ischemic conditions. @entity5 resection was done using an ultrasonic device (CUSA/SONOCA 300). @entity5 characteristics, perioperative, and postoperative variables were evaluated. RESULTS: The median age was 60.0  years (range 40-76); body mass index 28.0  kg/m(2) (range 22.9-43.3); @entity5 size 37.0  mm (range 11-110  mm). @entity1 were stratified according to the PADUA score into low- (score 6-7; n  -  4), intermediate- (score 8-9; n  -  5), and high-risk (score of >10; n  -  4) groups, and the median score was 9.0 (range 6-13; SD +2.3). The vast majority of @entity703 were diagnosed incidentally (n  -  11; 84.6  %). Median operative time was 175  min (55-270  min); median time of @entity5 extirpation was 12  min (6-25  min); and median @entity190 was 250  ml. Serum @entity1011 , glomerular filtration rate, and hemoglobin were nearly unaltered before and after surgery in 11 cases (84.6  %). Three @entity1 received a blood transfusion (Clavien-Dindo Grade II); one had Grade IIIa complication (insertion of double J stent without general anesthesia); and three had @entity532 (insertion of double J under general anesthesia). CONCLUSIONS: The ultrasonic device demonstrated acceptable hemostatic and resection properties during open partial nephrectomy without @entity63 . Our series showed promising perioperative and postoperative outcomes that may help in maximizing preservation of renal function in partial nephrectomy candidates.

title: Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero XXXX : a pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Demographic and laboratory data, tumor', 'Tumor']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['Grade IIIb complications']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['kidney tumors', 'renal tumors']

answer: @entity63 :: (MESH:D007511,Disease) :: ['ischemia']


abstract: UNASSIGNED: Furfural and @entity1543 from lignocellulosic hydrolysates are the prevalent inhibitors to @entity15548 during cellulosic @entity1068 production. Developing a strain tolerant to furfural or @entity1543 inhibitors is difficul by using rational engineering strategies due to poor understanding of their underlying molecular mechanisms. In this study, strategy of adaptive laboratory evolution (ALE) was used for development of a furfural and @entity1543 -tolerant strain. After three round evolution, four evolved mutants (ZMA7-2, ZMA7-3, ZMF3-2, and ZMF3-3) that showed higher growth capacity were successfully obtained via ALE method. Based on the results of profiling of cell growth, @entity413 utilization, @entity1068 yield, and activity of key enzymes, two desired strains, ZMA7-2 and ZMF3-3, were achieved, which showed higher tolerance under 7  g/l @entity1543 and 3  g/l furfural stress condition. Especially, it is the first report of @entity15548 that could tolerate higher furfural. The best strain, @entity15548 ZMF3-3, has showed 94.84  % theoretical @entity1068 yield under 3-g/l furfural stress condition, and the theoretical @entity1068 yield of ZM4 is only 9.89  %. Our study also demonstrated that ALE method might also be used as a powerful metabolic engineering tool for metabolic engineering in @entity15548 . Furthermore, the two best strains could be used as novel host for further metabolic engineering in cellulosic @entity1068 or future biorefinery. Importantly, the two strains may also be used as novel-tolerant model organisms for the genetic mechanism on the "omics" level, which will provide some useful information for inverse metabolic engineering.

title: Adaptive laboratory evolution of ethanologenic XXXX tolerant to furfural and @entity1543 inhibitors.

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity15548 :: ('542', 'Species') :: ['Zymomonas mobilis', 'Z. mobilis strain', 'Z. mobilis']

entities_list: @entity1543 :: ('MESH:D019342', 'Chemical') :: ['acetic acid']

answer: @entity15548 :: (542,Species) :: ['Zymomonas mobilis strain']


abstract: UNASSIGNED: Furfural and @entity1543 from lignocellulosic hydrolysates are the prevalent inhibitors to @entity15548 during cellulosic @entity1068 production. Developing a strain tolerant to furfural or @entity1543 inhibitors is difficul by using rational engineering strategies due to poor understanding of their underlying molecular mechanisms. In this study, strategy of adaptive laboratory evolution (ALE) was used for development of a furfural and @entity1543 -tolerant strain. After three round evolution, four evolved mutants (ZMA7-2, ZMA7-3, ZMF3-2, and ZMF3-3) that showed higher growth capacity were successfully obtained via ALE method. Based on the results of profiling of cell growth, @entity413 utilization, @entity1068 yield, and activity of key enzymes, two desired strains, ZMA7-2 and ZMF3-3, were achieved, which showed higher tolerance under 7  g/l @entity1543 and 3  g/l furfural stress condition. Especially, it is the first report of @entity15548 that could tolerate higher furfural. The best strain, @entity15548 ZMF3-3, has showed 94.84  % theoretical @entity1068 yield under 3-g/l furfural stress condition, and the theoretical @entity1068 yield of ZM4 is only 9.89  %. Our study also demonstrated that ALE method might also be used as a powerful metabolic engineering tool for metabolic engineering in @entity15548 . Furthermore, the two best strains could be used as novel host for further metabolic engineering in cellulosic @entity1068 or future biorefinery. Importantly, the two strains may also be used as novel-tolerant model organisms for the genetic mechanism on the "omics" level, which will provide some useful information for inverse metabolic engineering.

title: Adaptive laboratory evolution of ethanologenic @entity15548 tolerant to furfural and XXXX inhibitors.

answer: @entity1543 :: (MESH:D019342,Chemical) :: ['acetic acid']


abstract: The main aim of the present study was to gain insight into the stability of an anaerobic digestion process suffering from exposure to antibiotics and the methanogenic inhibitor @entity72039 ( @entity45940 ). For this purpose, eleven antibiotics and @entity45940 were investigated with regard to the degradation of volatile @entity1718 (VFAs), methanogenesis, and impact on the microbial community structure. Only @entity5154 , @entity801 , @entity1215 , and @entity45940 showed complete inhibitions of VFA degradations. This points to distinct interferences with important trophic degradation cascades. Based upon DGGE and sequencing approaches, Methanosarcina spp. were severely influenced by the treatments while hydrogenotrophic methanogens were less affected. Interestingly, @entity45940 and @entity5154 inhibited the degradation of @entity598 while only @entity45940 inhibited methanogenesis completely. It seems that Methanosarcina spp. were mandatory for the degradation of @entity598 at high rates. The present results highly emphasize the detrimental effects of antimicrobial compounds with the potential to significantly inhibit the anaerobic digestion.

title: Impact of several antibiotics and XXXX on the volatile fatty acid degradation, methanogenesis and community structure during thermophilic anaerobic digestion.

entities_list: @entity72039 :: ('MESH:C018853', 'Chemical') :: ['2-bromoethanesulfonate']

entities_list: @entity801 :: ('MESH:D005839', 'Chemical') :: ['gentamicin']

entities_list: @entity598 :: ('CHEBI:47622', 'Chemical') :: ['acetate']

entities_list: @entity5154 :: ('MESH:D009355', 'Chemical') :: ['neomycin']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

answer: @entity72039 :: (MESH:C018853,Chemical) :: ['2-bromoethanesulfonate']


abstract: The clinical picture, radiological findings and treatment of 22 @entity1 with @entity9807 and @entity309 are described. This lesion, untreated, may result in damage to the spinal cord, paresis or @entity944 . @entity10 , present in 13 of 22 @entity1 , was often aggravated by working with the head in forward flexion. Paresthesias were present in six @entity1 . The spine of the @entity2270 was often prominent. In three @entity1 there was objective evidence of @entity1745 with sensory and/or pyramidal signs. In eight the lesion was asymptomatic and discovered by routine lateral radiography in flexion, the position of maximum subluxation.Conservative treatment involved the continuous use of a cervical collar to limit neck flexion. This usually relieved subjective symptoms including @entity10 . Successful surgical fixation was performed in two individuals. Surgical indications included @entity1745 or severe symptoms unrelieved by a collar.

title: XXXX and its clinical presentation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden death']

entities_list: @entity1745 :: ('MESH:D013117', 'Disease') :: ['cord compression', 'acute or chronic cord compression']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['Occipital headache', 'headaches']

entities_list: @entity9807 :: ('MESH:C538196', 'Disease') :: ['atlantoaxial subluxation']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

answer: @entity309 :: (MESH:D001172,Disease) :: ['Rheumatoid arthritis--atlanto-axial subluxation']


abstract: UNASSIGNED: Epithelioid @entity3620 ( @entity3620 ) can easily be confused with @entity2220 ( @entity420 ). In serous effusion, @entity14187 is shown to be useful in the diagnosis of @entity2615 vs @entity420 . @entity72040 is reported to be overexpressed in epithelioid @entity2615 and absent in @entity1 airway epithelium. The aim was to assess the value of @entity14187 and @entity17290 compared to that of BerEp4 and @entity7457 ( @entity7457 ) in differentiating lung ACA from epithelioid @entity3620 and to examine the expression of @entity72040 in these @entity5 . The expression of @entity14187 , @entity17290 , @entity72040 , BerEp4, and @entity7457 was examined by immunohistochemistry in a total of 62 @entity1 specimen including 28 epithelioid MPMs and 34 @entity420 of the lung. In lung ACA, @entity17290 was strongly expressed in all 34 (100%) specimens followed by @entity14187 in 33 (97%) of 34. BerEp4 was expressed in 32 (94.1%) of 34. @entity7457 reacted for only 20 (58.82%) of 34 cases of lung ACA. In @entity3620 specimens, the expression of @entity21487 as well as that of @entity7457 was completely absent. In contrast, BerEp4 was focally expressed in 5 (17.85%) of 28 cases of epithelioid @entity3620 . @entity72040 was strongly expressed in 53% pf epithelioid MPMs but also in 50% of lung @entity420 . Its expression was moderate in normal pleura and limited in normal lung. @entity14187 and @entity17290 appear to be the best performing @entity189 markers in discriminating lung ACA from @entity2615 compared with BerEp4 and @entity7457 . There is no differential expression of @entity72040 between the 2 pathologies. However, the limited @entity72040 expression in normal tissues and high expression in @entity5 make it an attractive candidate for @entity5 therapy.

title: XXXX , 4, and 15 expression in solid tumors of lung adenocarcinoma versus @entity3620 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity2615 :: ('MESH:D008654', 'Disease') :: ['mesothelioma']

entities_list: @entity3620 :: ('MESH:C562839', 'Disease') :: ['MPM', 'malignant pleural mesothelioma']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinomas']

entities_list: @entity7457 :: ('7080', 'Gene') :: ['thyroid transcription factor-1', 'TTF1']

answer: @entity14187 :: (1365,Gene) :: ['Claudin 3']


abstract: UNASSIGNED: Epithelioid @entity3620 ( @entity3620 ) can easily be confused with @entity2220 ( @entity420 ). In serous effusion, @entity14187 is shown to be useful in the diagnosis of @entity2615 vs @entity420 . @entity72040 is reported to be overexpressed in epithelioid @entity2615 and absent in @entity1 airway epithelium. The aim was to assess the value of @entity14187 and @entity17290 compared to that of BerEp4 and @entity7457 ( @entity7457 ) in differentiating lung ACA from epithelioid @entity3620 and to examine the expression of @entity72040 in these @entity5 . The expression of @entity14187 , @entity17290 , @entity72040 , BerEp4, and @entity7457 was examined by immunohistochemistry in a total of 62 @entity1 specimen including 28 epithelioid MPMs and 34 @entity420 of the lung. In lung ACA, @entity17290 was strongly expressed in all 34 (100%) specimens followed by @entity14187 in 33 (97%) of 34. BerEp4 was expressed in 32 (94.1%) of 34. @entity7457 reacted for only 20 (58.82%) of 34 cases of lung ACA. In @entity3620 specimens, the expression of @entity21487 as well as that of @entity7457 was completely absent. In contrast, BerEp4 was focally expressed in 5 (17.85%) of 28 cases of epithelioid @entity3620 . @entity72040 was strongly expressed in 53% pf epithelioid MPMs but also in 50% of lung @entity420 . Its expression was moderate in normal pleura and limited in normal lung. @entity14187 and @entity17290 appear to be the best performing @entity189 markers in discriminating lung ACA from @entity2615 compared with BerEp4 and @entity7457 . There is no differential expression of @entity72040 between the 2 pathologies. However, the limited @entity72040 expression in normal tissues and high expression in @entity5 make it an attractive candidate for @entity5 therapy.

title: @entity14187 , 4, and 15 expression in solid tumors of lung adenocarcinoma versus XXXX .

answer: @entity3620 :: (MESH:C562839,Disease) :: ['malignant pleural mesothelioma']


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity6108 , green tea and @entity46927 . Previous reports have suggested that these agents can prevent @entity14 ( @entity14 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity2983 ( @entity3504 ) using the @entity8708 ( @entity18399 ) model in @entity35 . METHODS: The effect of Coltect was examined on HT-29 @entity14 cells by growth inhibition assay. Apoptosis was determined by @entity13909 - @entity2823 /PI staining. Male @entity35 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity3504 50   mg/kg or their combination, by oral gavage. @entity18432 ( @entity18432 ) were identified by @entity6693 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity5 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity18432 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity18432 similarly to @entity3504 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity694 cells, induces apoptosis and inhibits @entity18432 development. Furthermore, it augments the growth inhibitory effect of @entity3504 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity14 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with @entity2983 in @entity8708 -induced XXXX in @entity35 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity6693 :: ('MESH:D008751', 'Chemical') :: ['methylene blue']

entities_list: @entity6108 :: ('MESH:D003474', 'Chemical') :: ['curcumin']

entities_list: @entity8708 :: ('MESH:D019813', 'Chemical') :: ['1,2-dimethylhydrazine']

entities_list: @entity18432 :: ('MESH:D058739', 'Disease') :: ['Aberrant crypt foci', 'ACF']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer']

entities_list: @entity46927 :: ('MESH:D012645', 'Chemical') :: ['selenomethionine']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer']

entities_list: @entity2983 :: ('MESH:D019804', 'Chemical') :: ['5-aminosalicylic acid']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colon cancer']


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity6108 , green tea and @entity46927 . Previous reports have suggested that these agents can prevent @entity14 ( @entity14 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity2983 ( @entity3504 ) using the @entity8708 ( @entity18399 ) model in @entity35 . METHODS: The effect of Coltect was examined on HT-29 @entity14 cells by growth inhibition assay. Apoptosis was determined by @entity13909 - @entity2823 /PI staining. Male @entity35 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity3504 50   mg/kg or their combination, by oral gavage. @entity18432 ( @entity18432 ) were identified by @entity6693 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity5 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity18432 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity18432 similarly to @entity3504 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity694 cells, induces apoptosis and inhibits @entity18432 development. Furthermore, it augments the growth inhibitory effect of @entity3504 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity14 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with @entity2983 in XXXX -induced @entity694 in @entity35 .

answer: @entity8708 :: (MESH:D019813,Chemical) :: ['1,2-dimethylhydrazine']


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity6108 , green tea and @entity46927 . Previous reports have suggested that these agents can prevent @entity14 ( @entity14 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity2983 ( @entity3504 ) using the @entity8708 ( @entity18399 ) model in @entity35 . METHODS: The effect of Coltect was examined on HT-29 @entity14 cells by growth inhibition assay. Apoptosis was determined by @entity13909 - @entity2823 /PI staining. Male @entity35 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity3504 50   mg/kg or their combination, by oral gavage. @entity18432 ( @entity18432 ) were identified by @entity6693 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity5 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity18432 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity18432 similarly to @entity3504 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity694 cells, induces apoptosis and inhibits @entity18432 development. Furthermore, it augments the growth inhibitory effect of @entity3504 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity14 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with XXXX in @entity8708 -induced @entity694 in @entity35 .

answer: @entity2983 :: (MESH:D019804,Chemical) :: ['5-aminosalicylic acid']


abstract: OBJECTIVES: Coltect is a novel dietary supplement containing @entity6108 , green tea and @entity46927 . Previous reports have suggested that these agents can prevent @entity14 ( @entity14 ). The present study examined the chemopreventive effect of Coltect alone or combined with @entity2983 ( @entity3504 ) using the @entity8708 ( @entity18399 ) model in @entity35 . METHODS: The effect of Coltect was examined on HT-29 @entity14 cells by growth inhibition assay. Apoptosis was determined by @entity13909 - @entity2823 /PI staining. Male @entity35 were injected with DMH in vivo and treated with Coltect 150   mg/kg, @entity3504 50   mg/kg or their combination, by oral gavage. @entity18432 ( @entity18432 ) were identified by @entity6693 staining. RESULTS: HT-29 cells exhibited a dose-dependent response to Coltect. Part of the growth inhibition can be explained by the induction of mild-moderate apoptosis in @entity5 cells (28%) compared with the untreated cells (10%). In the in vivo model, the average number of @entity18432 was divided into small (1-3 crypts) or large (>= 4 crypts). The Coltect compound reduced the number of small and large @entity18432 similarly to @entity3504 (40% reduction). This reduction was amplified by combining the two agents (70% reduction). CONCLUSION: Coltect inhibits the growth of @entity694 cells, induces apoptosis and inhibits @entity18432 development. Furthermore, it augments the growth inhibitory effect of @entity3504 in vivo. This may be clinically important since this safe dietary supplement-drug combination can be administered as a chemopreventive regimen for the treatment of @entity14 .

title: Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with @entity2983 in @entity8708 -induced @entity694 in XXXX .

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: BACKGROUND: @entity618 ( @entity2098 ) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. OBJECTIVE: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral @entity2098 in @entity15 ( @entity15 ). METHODS: Twenty-four treatment-na  ve R-RMS @entity1 participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every @entity1 injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1   :   1) to either active oral @entity2098 or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. RESULTS: In this small pilot investigation, no differences were identified between the two treatment groups with respect to @entity1 -reported adverse events, MRI metrics, or @entity854 . Notwithstanding these observations, and the limited number of @entity1 treated, trends appeared to favor the combination therapy regimen. CONCLUSIONS: The combination treatment regimen of interferon beta-1a and @entity2098 appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of @entity2098 in @entity15 appears warranted.

title: A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and @entity618 in early relapsing-remitting @entity15 (TIME XXXX ).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['laboratory abnormalities']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['Mycophenolate mofetil']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis']

answer: @entity15 :: (MESH:D009103,Disease) :: ['MS']


abstract: BACKGROUND: @entity618 ( @entity2098 ) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. OBJECTIVE: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral @entity2098 in @entity15 ( @entity15 ). METHODS: Twenty-four treatment-na  ve R-RMS @entity1 participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every @entity1 injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1   :   1) to either active oral @entity2098 or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. RESULTS: In this small pilot investigation, no differences were identified between the two treatment groups with respect to @entity1 -reported adverse events, MRI metrics, or @entity854 . Notwithstanding these observations, and the limited number of @entity1 treated, trends appeared to favor the combination therapy regimen. CONCLUSIONS: The combination treatment regimen of interferon beta-1a and @entity2098 appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of @entity2098 in @entity15 appears warranted.

title: A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and @entity618 in early relapsing-remitting XXXX (TIME @entity15 ).

answer: @entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']


abstract: BACKGROUND: @entity618 ( @entity2098 ) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. OBJECTIVE: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral @entity2098 in @entity15 ( @entity15 ). METHODS: Twenty-four treatment-na  ve R-RMS @entity1 participated in a one-year prospective, placebo-controlled, blinded, safety pilot clinical trial. Every @entity1 injected weekly intramuscular interferon beta-1a. The cohort was then randomized (1   :   1) to either active oral @entity2098 or identical-appearing placebo tablets. Clinical evaluations were assessed every 3 months, along with brain MRI scans performed at baseline and repeated every 60 days for one year. Comprehensive laboratory assessments were monitored for safety, along with adverse events. RESULTS: In this small pilot investigation, no differences were identified between the two treatment groups with respect to @entity1 -reported adverse events, MRI metrics, or @entity854 . Notwithstanding these observations, and the limited number of @entity1 treated, trends appeared to favor the combination therapy regimen. CONCLUSIONS: The combination treatment regimen of interferon beta-1a and @entity2098 appeared to be well tolerated in this pilot study. Despite the small sample size, therapeutic trends were observed in favor of combination therapy. An adequately powered controlled trial of @entity2098 in @entity15 appears warranted.

title: A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and XXXX in early relapsing-remitting @entity15 (TIME @entity15 ).

answer: @entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']


abstract: UNASSIGNED: @entity2783 is a heterogeneous group of protein misfolding diseases characterized by deposition of amyloid proteins. The kidney is frequently affected, especially by immunoglobulin light chain ( @entity1582 ) and @entity5475 ( @entity5475 ) @entity2783 as the most common subgroups. Current diagnosis relies on histopathological examination, Congo red staining, or electron microscopy. Subtyping is done by immunohistochemistry; however, commercially available antibodies lack specificity. The purpose of this study was to identify and map amyloid proteins in formalin-fixed paraffin-embedded tissue sections using matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis in an integrated workflow. @entity12042 and @entity2783 biopsies were processed for histological and MS analysis. Mass spectra corresponding to the congophilic areas were directly linked to the histological and MS images for correlation studies. Peptides for @entity5475 and @entity1582 were detected by MALDI IMS associated to Congo red-positive areas. Sequence determination of amyloid peptides by LC-MS/MS analysis provided protein distribution and identification. Serum amyloid P component, @entity2204 , and @entity4732 proteins were identified in both @entity5066 and @entity1582 , showing a strong correlation with Congo red-positive regions. Our findings highlight the utility of MALDI IMS as a new method to type @entity2783 in histopathological routine material and characterize amyloid-associated proteins that may provide insights into the pathogenetic process of amyloid formation.

title: Imaging mass spectrometry analysis of XXXX biopsies reveals protein co-localization with amyloid deposits.

entities_list: @entity12042 :: ('MESH:C538249', 'Disease') :: ['Renal amyloidosis']

entities_list: @entity2204 :: ('348', 'Gene') :: ['apolipoprotein E']

entities_list: @entity2783 :: ('MESH:D000686', 'Disease') :: ['Amyloidosis', 'non-amyloidosis', 'amyloidosis']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['AL amyloidosis', 'AL']

answer: @entity12042 :: (MESH:C538249,Disease) :: ['renal amyloidosis']


abstract: PURPOSE: to examine the association between cytogenetic characteristics and clinical and epidemiological changes in @entity1 with @entity2689 ( @entity2689 ). METHODS: Forty-two @entity1 were included. Data were collected using a standardized questionnaire in interviews conducted with the responsible @entity1 and, when possible, with the @entity1 . A detailed physical examination was performed. The association between karyotype, stigmata and clinical disorders were examined using the   2 test. RESULTS: Sixty-four percent of @entity2689 @entity1 were 45,X; 26,2% 45,X/46,X;7% 45,X/46Xi(Xq), and 2,3% 45,X/46,X,Del(Xq). Regardless of the karyotype, all @entity1 had @entity851 . Low hair implantation was more frequent in @entity1 with 45,X (p=0.03). @entity65 (45%), @entity2346 (43%), @entity1374 (33%) and @entity101 (26.6%) were the most frequent clinical disorders, but without correlation with the karyotype. Anthropometric measurements revealed a positive linear correlation of waist and hip circumference with age (r=0.9, p=0.01). Thirty-one @entity1 (74%) were using or had previously used growth hormone (43%), sex @entity230 (30%), @entity1955 (11.9%) or @entity7786 (9.5%). Comparison between gestational age at birth and learning difficulties showed a prevalence ratio of 1.71 (p>0.05). CONCLUSION: Low hair implantation is the most prevalent stigma in @entity1 with a 45,X karyotype and the most common clinical changes were cardiovascular problems, @entity2346 , @entity1374 and @entity101 ; however, they did not show any correlation with the karyotype.

title: [Clinical and cytogenetic aspects of the XXXX in the Brazilian Western region].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'person']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['short stature']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity1955 :: ('MESH:D013974', 'Chemical') :: ['thyroxine']

entities_list: @entity7786 :: ('MESH:D010074', 'Chemical') :: ['oxandrolone']

entities_list: @entity2689 :: ('MESH:D014424', 'Disease') :: ['Turner syndrome', 'TS']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['Cardiovascular abnormalities']

entities_list: @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid dysfunction']

answer: @entity2689 :: (MESH:D014424,Disease) :: ['Turner syndrome']


abstract: BACKGROUND: Myocardial @entity1063 is altered in left @entity67 . In @entity1 with @entity296 ( @entity296 ), this issue has not been addressed. OBJECTIVE: To determine the level of myocardial @entity1063 in @entity1 with @entity296 and compare it in @entity1 with @entity453 , and to relate myocardial @entity1063 to left ventricular ejection fraction (LVEF). METHODS: We studied 39 @entity1 with @entity296 , divided into group 1: 21 individuals with normal LVEF and group 2: 18 individuals with decreased LVEF. Seventeen @entity1 with @entity453 were divided into group 3: 12 individuals with normal LVEF and group 4: 5 individuals with decreased LVEF. Two-dimensional echocardiography was used to measure LVEF. Myocardial @entity1063 was determined by high-performance liquid chromatography. RESULTS: Myocardial @entity1063 in @entity296 with and without @entity67 was 1.3  1.3 and 6.1  4.2 pg/ g noncollagen protein, respectively (p<0.0001); in @entity453 with and without @entity67 , it was 3.3  3.0 and 9.8  4.2 pg/ g noncollagen protein, respectively (p<0.0001). A positive correlation was found between LVEF and myocardial @entity1063 concentration in the @entity1 with @entity296 (p<0.01, r = 0.57) and also in those with @entity453 (p<0.01, r=0.69). A significant difference was demonstrated between @entity1063 concentrations in @entity1 with normal LVEF (groups 1 and 3; p = 0.0182), but no difference was found in @entity1 with decreased LVEF (groups 2 and 4; p = 0.1467). CONCLUSION: In @entity1 with @entity296 and normal global ejection fraction there is an early cardiac denervation, when compared to @entity453 @entity1 .

title: Intramyocardial adrenergic activation in chagasic XXXX and @entity453 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ["Chagas' cardiomyopathy", 'CC']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular impairment', 'ventricular dysfunction']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity296 :: (MESH:D009202,Disease) :: ['cardiomyopathy']